Company Overview

Sanofi was incorporated in 1994 and is headquartered in Paris, France. The company was formerly known as Sanofi-Aventis and officially changed its name to Sanofi in May 2011. Sanofi S.A. is a global healthcare company deeply committed to patient needs, engaging in the research, development, manufacture, and marketing of innovative therapeutic solutions across various medical disciplines.

Business Overview

Sanofi operates through three primary business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

- Pharmaceuticals: This segment encompasses the commercial operations of global franchises including specialty care, diabetes and cardiovascular, established prescription products, and generics. It also includes extensive research, development, and production activities.

- Consumer Healthcare: Focuses on over-the-counter (OTC) products that empower individuals to manage their health and well-being.

- Vaccines: Sanofi is a major global supplier of vaccines, protecting against a wide range of infectious diseases.

The company has established strong leadership positions in numerous therapeutic areas, offering medicines and vaccines for:

- Immunology and inflammation

- Rare diseases

- Neurology

- Oncology

Sanofi's vaccine portfolio includes critical immunizations such as:

- Pediatric vaccines for poliomyelitis, pertussis, and _Haemophilus influenzae_ type b (Hib).

- Respiratory syncytial virus (RSV) protection and hexavalent combination vaccines (protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B).

- Influenza, booster, meningitis, and travel/endemic vaccines, including those for hepatitis A, typhoid, yellow fever, and rabies.

Financial Performance and Market Position

Sanofi has demonstrated robust financial performance, underscored by consistent sales growth and strategic product portfolio expansion.

Recent Financial Results

- Q1 2025: Reported sales growth of 9.7% at constant exchange rates (CER), with business earnings per share (EPS) of €1.79, indicating a strong rebound expected for 2025.

- Q4 2024: Achieved sales growth of 10.3% at CER, with continued solid growth in sales and earnings anticipated throughout 2025.

Key Financial Metrics (2024)

- Business EPS: €7.12 in FY 2024 (a decrease of 1.8%, or +4.1% at CER).

- Average Number of Shares Outstanding: 1,251.4 million in FY 2024 (compared to 1,251.7 million in FY 2023).

Strategic Product Portfolio

Sanofi's growth is significantly driven by its flagship products and new launches.

Dupixent - Flagship Product

- Sales: Reached €3,458 million, marking a 16.0% increase.

- US Sales: Contributed €2,551 million, up by 10.4%.

- Outlook: Dupixent is projected to achieve sales of approximately €22 billion by 2030, aligning with the company's current strategic ambitions.

Growth in New Launches

- Sales from new medicines and vaccines grew by a remarkable 46.5% in Q1 2025.

- Pharma launches specifically achieved sales of €0.8 billion, an increase of 43.8% during the same period.

Strategic Partnerships and Collaborations

Sanofi actively leverages a broad network of strategic partnerships to accelerate innovation and expand its therapeutic reach:

- IgM Biosciences, Inc.: Collaboration to develop, manufacture, and commercialize IgM antibodies.

- Kymera Therapeutics, Inc.: Partnership to develop and commercialize protein degrader therapies targeting IRAK4 for immune-inflammatory diseases.

- Nurix Therapeutics, Inc.: Collaboration focused on developing novel targeted protein degradation therapies.

- Denali Therapeutics Inc.: Agreement to treat a range of systemic inflammatory diseases, including ulcerative colitis.

- Adagene Inc.: Partnership for the discovery and development of antibody-based therapies.

- Scribe Therapeutics Inc.: Collaboration to develop advanced genome editing technologies.

- Provention Bio, Inc.: Co-promotion service agreement for the commercialization of teplizumab.

- Department of Health – Abu Dhabi: Strategic alliance for the development of global vaccines.

Investment and Growth Strategy

Sanofi is committed to significant investment in Research & Development (R&D) to fuel its pipeline and future growth.

- R&D Investments: Increased R&D spending in 2024 has led to substantial pipeline progress.

- Pipeline Advancements: Achieved positive Phase 3 study results for new medicines, including rilzabrutinib (rare diseases) and tolebrutinib (multiple sclerosis).

- Share Buyback Program: Intends to complete a €5 billion share buyback program in 2025, with 72% already repurchased as part of its capital redeployment strategy.

2025 Outlook

Sanofi anticipates strong performance in 2025:

- Sales Growth: Mid-to-high single-digit percentage growth is expected at constant exchange rates (CER).

- Business EPS Growth: A strong rebound is confirmed, with growth projected at a low double-digit percentage at CER (before share buyback).

Pipeline Development

Significant advances have been made across Sanofi's pipeline:

- Approvals: Six new approvals have been secured.

- New Medicines: Steady progress has been made with numerous new medicines in respiratory diseases and dermatology.

- Amlitelimab: Demonstrated clinically meaningful efficacy in asthma, paving the way for Phase 3 development, poised to create future value for patients and the company.

- Qfitlia (fitusiran): Received approval as a new treatment for patients with hemophilia, representing one of three potential launches in the current year.

- ALTUVIIIO: Continues to gain market share and is on track to become Sanofi's next blockbuster product.

Sanofi continues to exhibit strong operational performance while strategically investing in innovation and pipeline development. This positions the company as a leading global healthcare enterprise with a diversified therapeutic portfolio and a robust trajectory for future growth.